Important Notice for Investors in Revance Therapeutics
Revance Therapeutics, Inc. (NASDAQ: RVNC) is currently facing legal challenges that could significantly impact its investors. As a valued shareholder, understanding your rights is vital, especially in light of a class action securities lawsuit initiated recently.
Understanding the Class Action Lawsuit
This lawsuit is aimed at recovering losses for those who have suffered due to alleged securities fraud connected to Revance. It specifically addresses claims from a time frame that raises serious concerns for many investors.
Who is Affected?
Investors who held shares between February 29, 2024, and December 6, 2024, may find themselves eligible to join this action. During this period, there were allegations that Revance made false statements or concealed significant information affecting its operations and market perception.
Details of the Allegations
According to the filed complaint, several critical issues were raised: Firstly, it is suggested that Revance was in breach of its Distribution Agreement with Teoxane, which gave the company exclusive rights to a profitable line of products. This breach could expose Revance to litigation and result in both monetary losses and reputational damage.
Taking Action
If you believe you were adversely affected during this critical timeframe, it’s essential to act before March 4, 2025. This is the deadline to request the court's appointment to serve as a lead plaintiff, although participating in any recovery does not necessarily require this role.
No Financial Risk to Participants
Engaging in this class action lawsuit carries no out-of-pocket costs for members. Compensation may be available without financial obligation, making participation low-risk for affected shareholders.
Why Choose Levi & Korsinsky?
Levi & Korsinsky, LLP has an established history of representing investors in complex securities litigation. Over two decades, they have achieved significant recoveries for shareholders, showcasing a strong track record in high-stakes cases. The firm is noted for its expertise in navigating such legal matters, with a robust team ready to assist clients throughout the process.
Contact Information for Assistance
For further information and guidance, shareholders can reach out to Joseph E. Levi, Esq. by telephone at (212) 363-7500. For email inquiries, you may contact his office directly using the provided details.
Frequently Asked Questions
What is the purpose of the class action lawsuit against Revance?
The class action lawsuit aims to recover losses for investors adversely affected by alleged securities fraud during a specified time frame.
Who can participate in the lawsuit?
Investors who held shares of Revance between February 29, 2024, and December 6, 2024, may be eligible to participate.
What are the costs involved in joining the class action?
There are no out-of-pocket costs for participants; involvement in the class action is free.
When is the deadline to act?
The deadline to request appointment as a lead plaintiff is March 4, 2025.
How can I get more information?
Investors can contact Levi & Korsinsky for further information about their rights and potential participation in the lawsuit.
